Kopp Investment Advisors LLC grew its stake in Teligent Inc (NASDAQ:TLGT) by 24.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 956,526 shares of the company’s stock after buying an additional 186,390 shares during the period. Teligent makes up approximately 3.5% of Kopp Investment Advisors LLC’s holdings, making the stock its 7th biggest position. Kopp Investment Advisors LLC owned about 1.79% of Teligent worth $3,472,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Columbus Circle Investors lifted its position in shares of Teligent by 54.6% in the third quarter. Columbus Circle Investors now owns 276,472 shares of the company’s stock worth $1,855,000 after buying an additional 97,642 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Teligent in the third quarter worth about $1,297,000. AMI Asset Management Corp lifted its position in shares of Teligent by 46.4% in the fourth quarter. AMI Asset Management Corp now owns 2,339,968 shares of the company’s stock worth $8,494,000 after buying an additional 741,818 shares during the last quarter. Pembroke Management LTD lifted its position in shares of Teligent by 2.9% in the third quarter. Pembroke Management LTD now owns 2,326,621 shares of the company’s stock worth $15,612,000 after buying an additional 65,200 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Teligent by 51.7% during the 3rd quarter. Stifel Financial Corp now owns 1,141,741 shares of the company’s stock worth $7,685,000 after purchasing an additional 389,307 shares during the last quarter. 68.36% of the stock is owned by institutional investors.
Teligent Inc (TLGT) opened at $2.69 on Monday. Teligent Inc has a 12-month low of $2.59 and a 12-month high of $9.54. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.